Guo Y, Ma M, Tian T, Zhang J, Guo X, Qiao S
Oncol Lett. 2024; 28(4):468.
PMID: 39119236
PMC: 11306990.
DOI: 10.3892/ol.2024.14601.
Morales-Camacho R, Caballero-Velazquez T, Borrero J, Bernal R, Prats-Martin C
Cancers (Basel). 2024; 16(2).
PMID: 38254826
PMC: 10814743.
DOI: 10.3390/cancers16020337.
Chu T, Huynh T, Nguyen K, Phu C
Hematol Transfus Cell Ther. 2023; 46(4):498-502.
PMID: 37316385
PMC: 11451361.
DOI: 10.1016/j.htct.2023.04.002.
Gotlib J
Hematology Am Soc Hematol Educ Program. 2022; 2022(1):34-46.
PMID: 36485158
PMC: 9821059.
DOI: 10.1182/hematology.2022000368.
Urrea Pineda L, Perilla O, Santiago-Pacheco V, Trujillo Montoya S
Cureus. 2022; 14(3):e22734.
PMID: 35386486
PMC: 8969320.
DOI: 10.7759/cureus.22734.
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.
Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E
Bone Marrow Transplant. 2022; 57(3):416-422.
PMID: 35066569
DOI: 10.1038/s41409-021-01553-x.
Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment.
Cowell J, Hu T
Cancer Drug Resist. 2021; 4:607-619.
PMID: 34734169
PMC: 8562765.
DOI: 10.20517/cdr.2021.30.
Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling.
Nita A, Abraham S, Krejci P, Bosakova M
Cells. 2021; 10(6).
PMID: 34207779
PMC: 8227969.
DOI: 10.3390/cells10061445.
[Inhibitory Eefects of the novel tyrosine kinase inhibitor BGJ398 against human leukemic cell line KG-1 cells].
Jiang Y, Chao H, Zhang X, Zhou M, Lu X, Zhang R
Zhonghua Xue Ye Xue Za Zhi. 2018; 39(2):143-147.
PMID: 29562450
PMC: 7342572.
DOI: 10.3760/cma.j.issn.0253-2727.2018.02.013.
Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.
Wang Y, Wu X, Deng J, Yu H, Xu R, Zhu Z
Cancer Biol Ther. 2016; 17(8):785-9.
PMID: 27415155
PMC: 5004680.
DOI: 10.1080/15384047.2016.1210727.
Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.
Yamamoto S, Otsu M, Matsuzaka E, Konishi C, Takagi H, Hanada S
PLoS One. 2015; 10(3):e0120841.
PMID: 25803811
PMC: 4372437.
DOI: 10.1371/journal.pone.0120841.
Fine-needle aspiration cytology of T-lymphoblastic lymphoma associated FGFR1 rearrangement myeloproliferative neoplasm.
Patel R, Sheehan A, Finch C, Lopez-Terrada D, Hernandez V, Curry C
Diagn Cytopathol. 2013; 42(1):45-8.
PMID: 23904402
PMC: 4100463.
DOI: 10.1002/dc.23030.
Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.
Ren M, Qin H, Kitamura E, Cowell J
Blood. 2013; 122(6):1007-16.
PMID: 23777766
PMC: 3739028.
DOI: 10.1182/blood-2013-03-489823.
Acute myeloid leukemia associated with FGFR1 abnormalities.
Lee H, Kim M, Lim J, Kim Y, Han K, Cho B
Int J Hematol. 2013; 97(6):808-12.
PMID: 23609419
DOI: 10.1007/s12185-013-1337-5.
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.
Ren M, Qin H, Ren R, Cowell J
Leukemia. 2012; 27(1):32-40.
PMID: 22781593
PMC: 3629706.
DOI: 10.1038/leu.2012.188.
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).
Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P
Haematologica. 2011; 96(6):922-6.
PMID: 21330321
PMC: 3105656.
DOI: 10.3324/haematol.2010.036558.
An alternative approach to medical genetics based on modern evolutionary biology. Part 4: HERVs in cancer.
Ryan F
J R Soc Med. 2009; 102(11):474-80.
PMID: 19875536
PMC: 2770355.
DOI: 10.1258/jrsm.2009.090289.
The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.
Goradia A, Bayerl M, Cornfield D
Int J Clin Exp Pathol. 2008; 1(5):448-56.
PMID: 18787627
PMC: 2480578.
14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.
Dong S, Kang S, Gu T, Kardar S, Fu H, Lonial S
Blood. 2007; 110(1):360-9.
PMID: 17389761
PMC: 1896121.
DOI: 10.1182/blood-2006-12-065615.
A novel chromosomal abnormality, t(6;10)(q27;q22), found in a polycythemic potential donor for allogeneic hematopoietic stem cell transplantation.
Mitsui H, Saito N, Satake A, Nakazawa T, Karasuno T, Hiraoka A
Int J Hematol. 2005; 82(1):72-4.
PMID: 16105764
DOI: 10.1532/IJH97.05027.